| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 656.4 | 653.0 |
| Gross profit | 328.6 | 343.4 |
| Profit before tax | 538.7 | -431.1 |
| Net income | 458.6 | -341.9 |
| EPS (diluted, $ a share) | $17.02 | $-12.70 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +0.5% |
|---|---|
| Gross margin | 50.1% |
| Operating margin | -7.6% |
10-Q filed with the SEC, NYSE: BIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bio-Rad Laboratories, Inc.: key numbers
- Share price
- $360.26Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bio-Rad Laboratories, Inc.
All →Bio-Rad Laboratories EVP, General Counsel & Sec Courtney C. Enloe Sells $348K of Stock
Courtney C. Enloe, EVP, General Counsel & Sec, sold 902 shares of Bio-Rad Laboratories, Inc. at $386.17 a share, worth $348K in total on Nov 10, 2026. Shares held after the trade: 750 (-54.6%).
- Value
- $348K
- Shares
- 902
- Price
- $386.17
- Role
- EVP, General Counsel & Sec
- Holding change
- -54.6%
- Trade date
- Nov 10, 2026
Bio-Rad Laboratories President & COO Jonathan P. DiVincenzo Sells $359K of Stock
Jonathan P. DiVincenzo, President & COO, sold 919 shares of Bio-Rad Laboratories, Inc. at $390.47 a share, worth $359K in total on Nov 9, 2026. Shares held after the trade: 1,962 (-31.9%).
- Value
- $359K
- Shares
- 919
- Price
- $390.47
- Role
- President & COO
- Holding change
- -31.9%
- Trade date
- Nov 9, 2026
Bio-Rad Laboratories EVP, President, LSG James Barry Sells $540K of Stock
James Barry, EVP, President, LSG, sold 1,400 shares of Bio-Rad Laboratories, Inc. at $385.63 a share, worth $540K in total on Nov 9, 2026. Shares held after the trade: 625 (-69.1%).
- Value
- $540K
- Shares
- 1,400
- Price
- $385.63
- Role
- EVP, President, LSG
- Holding change
- -69.1%
- Trade date
- Nov 9, 2026
Bio-Rad Laboratories Financial Results
Bio-Rad Laboratories reported third-quarter 2026 financial results with net sales of $656.4 million, representing a 0.7% increase on a currency-neutral basis. The company returned to growth driven by the Clinical Diagnostics segment and Droplet Digital PCR instruments, despite ongoing challenges in the academic research market. GAAP net income was significantly impacted by a change in the fair market value of the company's investment in Sartorius AG.
- Term
- Q3 2026
“Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments. Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives. The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook.”
Norman Schwartz, Bio-Rad’s Chief Executive Officer